15944-34-0

Usage

Uses

Used in Pharmaceutical Industry:
7-Chloro-[1,8]naphthyridin-2-ol is used as a building block for the synthesis of various pharmaceutical drugs. Its unique structure and functional groups make it a valuable component in the development of new medications.
Used in Antitumor Applications:
7-Chloro-[1,8]naphthyridin-2-ol has been studied for its potential biological activities, including its antitumor properties. It may be used as an antitumor agent, contributing to the development of new cancer treatments.
Used in Anti-Inflammatory Applications:
7-Chloro-[1,8]naphthyridin-2-ol has also shown potential as an anti-inflammatory agent. It may be utilized in the development of medications aimed at reducing inflammation and alleviating symptoms associated with inflammatory conditions.
Used in Drug Development:
7-Chloro-[1,8]naphthyridin-2-ol has been identified as a potential scaffold for the development of new therapeutic agents. Its unique structure and properties make it a promising candidate for further research and development in the pharmaceutical field.
However, it is important to note that further research is needed to fully understand the pharmacological properties and potential applications of 7-Chloro-[1,8]naphthyridin-2-ol. As our understanding of 7-Chloro-[1,8]naphthyridin-2-ol grows, so too may its applications and uses in various industries.

InChI:InChI=1/C8H5ClN2O/c9-6-3-1-5-2-4-7(12)11-8(5)10-6/h1-4H,(H,10,11,12)

Upstream product

• 1931-44-8 2-amino-7-hydroxy-1,8-naphthyridine 
• 141-86-6 2.6-diaminopyridine 
• 15944-33-9 2-chloro-7-amino-1,8-naphthyridine 
• 127446-41-7 6-Chloro-2-<(2,2-dimethyl-1-oxopropyl)amino>-β-hydroxy-3-pyridinepropanoic Acid, 1,1-Dimethylethyl Ester 
• 1931-44-8 2-amino-8H-7-oxo-[1,8]-naphthyridine 
• 86847-84-9 2,2-Dimethyl-N-(6-chloro-2-pyridinyl)propanamide 
• 127446-34-8 N-(6-chloro-3-formylpyridin-2-yl)-2,2-dimethylpropionamide 
• 45644-21-1 6-chloropyridin-2-amine 

Downstream Products

• 615568-69-9 methyl 7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridine-2-carboxylate 

Relevant academic research and scientific papers

Tailor-made naphthyridines: Self-assembling multiple hydrogen-bonded supramolecular architectures from dimer to helix

Stepwise changes of functional oxo and amino groups in 1,8-naphthyridines to modify the supramolecular architecture have been carried out. The first example of a naphthyridine helix has been found and its structure established by X-ray crystallography. The design is based on hydroxy and amido tautomeric naphthyridines which crystallize in dimers or catemers, one of them attaining helicity. The most stable tautomer present in all the compounds discussed in this paper, as well as the formation of hydrogen-bonded dimers or catemers, was established by X-ray crystallography and rationalized with theoretical calculations.

Unsymmetrical Naphthyridine-Based Dicopper(I) Complexes: Synthesis, Stability, and Carbon-Hydrogen Bond Activations

Two unsymmetrical dinucleating naphthyridine-based ligands with di(pyridyl) and phosphino side arms were employed in the synthesis of dicopper(I) chloride cores that activate NaBPh4to afford bridging phenyl organocopper complexes. In these compounds, the bridging ligand binds symmetrically, as observed in previously described symmetrical dicopper(I) complexes supported by naphthyridine-based ligands with two di(pyridyl) side arms. Unlike the symmetrical systems, however, these complexes undergo quasireversible electrochemical reductions, and chemical reduction yields a diamagnetic product resulting from the coupling of naphthyridine-based radicals of two complexes. The μ-Ph complexes activate the C-H bonds of terminal alkynes and the electron-poor arene C6F5H. By DFT calculations, the mechanism of terminal alkyne activation involves H-atom transfer at the cationic dicopper center and is sensitive to subtle changes in copper-ligand interactions as well as the position of the anion.

BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS

Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R 4, Y1, Y2, n and p are as defined herein.

NEW ANTIBACTERIAL COMPOUNDS

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

PIPERAZINE DERIVATIVE RENIN INHIBITORS

Disclosed are piperazine derivatives, their manufacture and use as inhibitors of renin. Formula (I):

A General Approach to the Synthesis of 1,6-, 1,7-, and 1,8-Naphthyridines

A new three-step procedure for pyridine annulation is described and illustrated with efficient syntheses of various 1,6-, 1,7-, and 1,8-naphthyridin-2-ones as well as 6-chloroquinolin-2-one.The regiospecific ortho metalation and subsequent formylation of